Sinopharm Group Shares Fall as Higher Costs Cut Into Quarterly Profit
By Amanda Lee
Sinopharm Group's shares fell by their most in more than six months in early trade after the Chinese state-owned pharmaceutical giant's quarterly profit fell amid higher operating costs and impairments.
Shares were down 6.4% at 20.45 Hong Kong dollars ($2.61) early Monday, taking them into the red for the year.
Sinopharm said ahead of trading that first-quarter profit dropped 11% from a year earlier to 1.42 billion yuan ($196 million). A 1.2% rise in total operating revenue was offset by a 1.5% rise in total operating cost, while credit impairment losses expanded 15% on year.
The company separately said its board had approved a plan to raise CNY30.0 billion via the issuance of corporate debt to repay loans and matured debt, replenish working capital and fund project construction, saying the moves would help trim financing costs and improve debt structure.
The issuance, which is subject to approval by shareholders and regulators, will comprise CNY25.0 billion in short-term debt with a one-year term and CNY5.0 billion in debt with a term of up to 10 years.
Write to Amanda Lee at amanda.lee@wsj.com
(END) Dow Jones Newswires
April 28, 2024 23:46 ET (03:46 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks